REVIEW

Novel Therapeutic and Prevention Approaches for Schistosomiasis: Review

Rashika A.F. El Ridi *, Hatem A.-M. Tallima

Zoology Department, Faculty of Science, Cairo University, Cairo 12613, Egypt

Received 1 April 2012; revised 12 May 2012; accepted 15 May 2012
Available online 23 June 2012

KEYWORDS
Schistosoma mansoni; Schistosoma haematobium; Schistosomicides; Arachidonic acid; Excretory-secretory products; Type 2 adjuvants

Abstract  Schistosomiasis is a debilitating disease affecting approximately 600 million people in 74 developing countries, with 800 million, mostly children at risk. To circumvent the threat of having praziquantel (PZQ) as the only drug used for treatment, several PZQ derivatives were synthesized, and drugs destined for other parasites were used with success. A plethora of plant-derived oils and extracts were found to effectively kill juvenile and adult schistosomes, yet none was progressed to pre- and clinical studies except an oleo-gum resin extracted from the stem of Commiphora molmol, myrrh, which action was challenged in several trials. We have proposed an essential fatty acid, a component of our diet and cells, the polyunsaturated fatty acid arachidonic acid (ARA) as a remedy for schistosomiasis, due to its ability to activate the parasite tegument-bound neutral sphingomyelinase, with subsequent hydrolysis of the apical lipid bilayer sphingomyelin molecules, allowing access of specific antibody molecules, and eventual worm attrition. This concept was convincingly supported using larval and adult Schistosoma mansoni and Schistosoma haematobium worms in in vitro experiments, and in vivo studies in inbred mice and outbred hamsters. Even if ARA proves to be an entirely effective and safe therapy for schistosomiasis, it will not prevent reinfection, and accordingly, the need for developing an effective vaccine remains an urgent priority. Our studies have supported the status of S. mansoni calpain, glutathione-S-transferase, aldolase, triose phosphate isomerase, glyceraldehyde 3-phosphate dehydrogenase, enolase, and 2-cys peroxiredoxin as vaccine candidates, as they are larval excreted-secreted products and, contrary to the surface membrane molecules, are entirely accessible to the host immune system effector elements. We have proposed that the use of these molecules, in conjunction with Th2 cytokines-inducing adjuvants for recruiting and activating eosinophils and basophils, will likely lead to development and implementation of a sterilizing vaccine in a near future.

© 2012 Cairo University. Production and hosting by Elsevier B.V. All rights reserved.

* Corresponding author. Tel.: +20 2 35676708; fax: +20 2 37603735.
E-mail address: rashika@mail.eun.eg (R.A.F. El Ridi).
Peer review under responsibility of Cairo University.

Schistosomiasis

Schistosomiasis, a debilitating disease endemic in 74 countries of the developing world, does not affect 207 million people as reported in 2006 [1], as recent articles document infection of 391–597 million people, with 800 million, mostly children, at

http://dx.doi.org/10.1016/j.jare.2012.05.002
risk of the infection [2–4]. Additionally, schistosomiasis does not cause the annual loss of between 1.7 and 4.5 [1], but between 24 and 56 [2], and up to 70 [3,4] million disability adjusted life years. Egyptian health authorities and public media continuously advocate the near elimination of schistosomiasis from Egypt, statement that was not denied by the patients in rural populations because of the stigma of poverty and social status inferiority linked to this infection. Yet, several articles document that Egypt has more than 10 million persons infected with schistosomes [2,5,6]. An article published in 2012 reports that Egypt is the MENA (Middle East North African) country with the highest prevalence (7.2 out of 80.4 million people, about 9%) of schistosomiasis [7]. This controversy must be laid at rest via generation or publication of objective, and scientifically valid data regarding the present prevalence of schistosomiasis in Egypt.

Schistosomiasis is caused by the platyhelminth worms of the genus Schistosoma, trematodes that live in the bloodstream of humans and animals. Three species (Schistosoma mansoni, Schistosoma haematobium and Schistosoma japonicum) account for the majority of human infections. Cercariae break out of the snail tissues into the water, swimming actively till dying or penetrating the unbroken skin of humans or animals, the definitive host, where they change into schistosomula. During the first 24 h after infection, nearly 90% of S. mansoni and S. haematobium schistosomula are present only in the blood-free, lymph-free epidermis. Majority of schistosomula are found in the dermis only after 48 h, and they appear to reach the dermal vessels around 72 h after infection [8,9]. Once in the blood capillaries, the schistosomula are carried passively by the blood flow till reaching the right heart and then the lungs. Depending on the species, schistosomula stay inside the pulmonary capillaries from 3 to 16 days, where they change into much longer and slender organisms, such a shape that enables them to traverse the thin pulmonary capillaries to the left heart and the systemic circulation [10]. Following this period, the larvae make their way to the liver via the splanchic vasculature. Upon reaching the liver, schistosomula start feeding and growing by active cell division. Once they reach maturity the worms start pairing, between 28 and 35 days post-infection. The paired adults migrate out of the liver, with the male carrying the eggs to the female, to where they will finally reside in the mesenteric veins (S. mansoni), or in the pelvic venous plexus and veins around the bladder (S. haematobium) [11,12]. Massive numbers of daily deposited eggs must traverse the walls of the blood vessels to enter the lumen of the intestine or bladder, to be excreted with the feces or urine. The morbidity associated with schistosomiasis results from the immunologic reactions to egg-derived antigens, beside the mechanical and toxic irritation caused by eggs trapped in the wall of blood vessels [11–14]. Some of the most common pathological changes seen in chronic schistosomiasis infections include bleeding into the intestine or urinary system, liver and spleen enlargement, and periportal fibrosis [11–14]. A connection between the chronic urinary form of schistosomiasis and bladder cancer is suspected [12,14].

In addition to the severe sequelae of schistosomiasis, the infection, even light, predisposes the host to, and accelerates the course and increases the severity of, infection with human immunodeficiency [15,16], and hepatitis B and C (HCV) viruses. For example, Egypt has the highest prevalence of HCV being > 15% in rural areas where schistosomiasis is endemic, whereby co-infection with schistosomiasis causes more severe liver disease than infection with HCV alone [17,18]. Infection with schistosomes renders the host particularly susceptible to mycobacteria, and protozoa, especially of the genus Plasmodium, Leishmania, Toxoplasma, and Trypanosoma [reviewed in 19].

**Schistosomicides**

Antimonial compounds, usually used for cure of leishmaniasis, have been the cornerstone of schistosome chemotherapy for about 50 years. Their mode of action is believed to be strong inhibition of the schistosome phosphofructokinase (the enzyme catalyzing the conversion of fructose-6-phosphate to fructose-1,6-diphosphate) at concentrations 65–80 times lower than those effective against the human enzyme [20]. This wide difference indicates that inhibition of host phosphofructokinase cannot be the only cause for the antimonials' excessive toxicity and severe side effects, which have rendered them now obsolete.

The organophosphorus insecticide 2,2,2-trichloro-1-hydroxyethyl dimethyl phosphonate was slightly modified to give rise to metrifonate (O,O-dimethyl-2,2,2-trichloro-1-hydroxyethylphosphonate), which has showed constant activity against S. haematobium. Mefronate is administered orally, and is metabolized leading to several byproducts, among which dichlorvos is the most potent, inducing schistosome acetylcholinesterase inhibition with subsequent reversible paralysis of the worm [21,22]. Paralyzed schistosomes lose their hold on the inner wall of blood vessels and are swept away with the blood stream, S. mansoni to the liver and S. haematobium to the lungs via the vena cava. Upon drug concentration decrease, S. mansoni are capable of regaining their original location in the mesenteric veins, whereas S. haematobium remain trapped in the lungs [23]. This might explain that metrifonate mediates killing of S. haematobium but not S. mansoni. It is of note that the drug also depresses host plasma and erythrocyte cholinesterase, explaining the severe side effects: fatigue, muscular weakness, tremor, sweating, fainting, diarrhea, nausea, vomiting, bronchospasm, consequences of cholinergic stimulation. Besides, three oral doses are absolutely required to reach a cure rate of 90%. This might explain why metrifonate has been taken out of the World Health Organization (WHO) list of essential drugs [24], leaving oxamniquine and praziquantel the only available drugs for treating schistosomiasis.

Oxamnique, 1,2,3,4-tetrahydro-2-(isopropylamino)methyl(-)7-nitro-6-nitro-quinoline methanol, when administered orally is effective against S. mansoni, male worms being more affected than females, while it has no effect on S. haematobium. A single, two or three oral doses of 20 mg/kg each, are needed for a cure rate of 80–90%, depending on the geographic region. After a curative dose in healthy volunteers, peak plasma concentrations of 1–4 mg/L are reached in 1–4 h and the plasma half-life is of the order of 1.5–2 h. Oxamniquine concentrations of 40 μg/mL are also lethal to adult S. mansoni in vitro [25,26]. It is now believed that oxamniquine undergoes esterification by a sulfotransferase uniquely present in sensitive schistosomes. The ester spontaneously dissociates, yielding an electrophilic reactant capable of alkylation schistosome DNA, with subsequent inhibition of DNA and RNA synthesis; the absence of this enzyme in mammals, including humans, explains the low toxicity of oxamniquine [27]. Resistance to oxamniquine has emerged in various foci, perhaps due to a mutation in the schistosome gene encoding the critical bioactivating (esterifying) enzyme [27,28].
Oxamniquine is used on a large scale only in Brazil. For the rest of the world, a single drug is now in use for treatment of schistosomiasis: praziquantel.

Praziquantel (PZQ), a pyrazino-isooquinoline derivative is practically insoluble in water, sparingly soluble in ethanol, but very soluble in chloroform and dimethyloxide. It is the drug of choice for treatment of all five species of human schistosomes, leading to cure rates of 60–90% in different epidemiological settings [29,30]. Adult schistosomes exposed in vitro to 1–3 μM PZQ undergo almost immediate spastic paralysis. In parallel, vacuolization of parts of the tegument and surface blebbing occur, especially in male worms (Table 1). All worms die thereafter. These reproducible findings indicate that adult schistosomes bind PZQ, and that PZQ per se is schistosomicidal [31]. In vivo, plasma concentrations of 1–10 μM are readily reached after a standard curative dose. In vivo, PZQ-induced muscle contraction and tegumental lesions produce a loss of attachment to the endothelial veins and dislodgment to the liver. Host cells of the defense system attach to the tegumental vacuoles and start to penetrate to the interior of the parasite early after treatment [28,32–34].

Despite that the initial effects of the drug included a rapid influx of calcium into the worm and calcium-dependent muscle contraction and paralysis, the exact mode of action of PZQ is not known as yet [35–38], and the PZQ receptor on schistosomes remains elusive [38,39]. One hypothesis to explain PZQ mode of action is that this drug inserts itself in the membrane producing lipid phase transition [40] and subsequent destabilizing effects on the membrane [41]. It is certainly documented that PZQ interacts with the surface tegument and severely damages it [42].

Control initiatives in numerous countries, including Egypt, rely on large-scale administration of PZQ [43–47]. Therefore, reports of low drug efficacy [48–50] and schistosome resistance to the drug [39,51–55] have raised intense alarm. The likely possibility that PZQ binds and polymerizes schistosome and mammalian actin [56–60] should preclude its use in children, pregnant women, and individuals with vascular diseases [61].

### Novel therapeutic approaches

**PZQ derivatives and combination chemotherapy**

Intense efforts are now directed at circumventing the flaw of having a single drug for such a dreadful infection via synthesizing derivatives of PZQ [39,62] and benzodiazepine schistosomicides [63], and examining their schistosomicidal activity in vitro and in vivo. Additionally, attempts were conducted to use PZQ in combination with other potential schistosomicides such as artemether [64–68], or hepatoprotective remedies [69,70] in an aim to reduce the PZQ dose, potentiate its schistosomicidal action, and alleviate side effects in experimental hosts.

**Novel drugs**

Several drugs targeting other parasites were tested for potential schistosomicidal activity (Table 1). The anti malarial drug artemether, a methoxy derivative of artemisinin, has been shown to be active against *S. japonica*, *S. mansoni*, and *S. haematobium* in experimentally infected animals [71]. A single oral injection of 400 mg/kg artemether to mice infected with approximately 80 cercariae of *S. mansoni* 21 (pre-patent) or 49 (patent period) days earlier led to 71–81% reduction in total worm burden [72–75]. Mefloquine, another anti-malarial drug, was also found to have significant anti-schistosome activity in vitro, and in vivo as well, as a single dose (200 or 400 mg/kg), administered orally to mice infected with adult *S. mansoni*, resulted in high worm burden reductions of 72.3–100% [76,77]. It has been shown that artemether interacts with haemin to exert a toxic effect on schistosomes, while mefloquine is believed to inhibit hemozoin formation. Yet, there are objections regarding a possible interference with the primary use of artemether and mefloquine as antimalarials [71–77]. Trioxolanes, which were considered for their potent anti-malarial activity, showed significant schistosomicidal activity in vitro and in vivo against *S. mansoni* and *S. japonicum* [78]. Acyclic nucleotide analogues, such as (S)-9-[3-hydroxy-2-(phosphonomethoxy) propyl]adenine [(S)-HPMPA] and their derivatives, possess effective broad-spectrum activity against many viruses via inhibition of DNA polymerase and/or reverse transcriptase, and were found to be actively schistosomicidal in vivo and in vitro [79,80]. The anti-microbial and anti-cancer oxadiazoles, which are five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom, have been found to possess inhibitory activity against *S. mansoni* and *S. japonicum* redox protein thioredoxin-glutathione reductase [81,82]. Trioxaquines, hybrid drugs containing a 1,2,4-trioxane and a 4-aminoquinoline, initially developed against malaria, exhibit a dual mode of action: alkylation of heme with the trioxane

---

**Table 1**  Schistosomicides target and mechanism of action.

| Drug               | Mode of action                                           | References |
|--------------------|----------------------------------------------------------|------------|
| Antimonials        | Inhibition of schistosome phosphofructokinase            | [20]       |
| Metronidazole      | Schistosome acetylcholinesterase inhibition and paralysis | [22]       |
| Oxamniquine        | Mediates inhibition of parasite DNA and RNA synthesis    | [27]       |
| Praziquantel       | Still elusive; binding to parasite calcium channels?     | [35–38]    |
|                    | Tegument disruption?                                     | [40–42]    |
|                    | Binding and polymerization of actin?                     | [56–60]    |
|                    | Exposure of surface membrane antigens                    | [33,34]    |
| Artemether         | Interacts with haemin                                    | [71–74]    |
| Mefloquine         | Inhibits hemozoin formation                              | [76]       |
| Acyclic nucleotide analogues | Inhibit parasite DNA polymerase?                       | [79,80]    |
| Oxadiazoles        | Inhibit parasite thioredoxin-glutathione reductase       | [81,82]    |
| Trioxaquines       | Alkylation of, and stacking with, heme                   | [83]       |
| Myrrh              | Worm uncoupling and extravasation                        | [98]       |
entity, and stacking with heme due to the aminooquinoline moiety, leading to inhibition of hemozoin formation in vitro, thus explaining their potent anti-S. mansoni activity in vitro and in vivo [83]. Imidazolines, pentagonal heterocyclic compounds with broad biological anti-microbial and anti-fungal activities, were considered for treatment of schistosomiasis because of their potent in vitro schistosomicidal effects [84]. Of great interest is the class of compounds targeting schistosome histone modifying enzymes, namely histone acetyltransferases and histone deacetylases, and leading to parasite apoptosis and death in in vitro cultures [85].

Plant-derived schistosomicidal compounds

A different approach to therapy of schistosomiasis relied on plants known for medicinal effects. Extracts and oils of several medicinal plants were tested for potential therapeutic activity against schistosome infection [86,87], and were exhaustively compiled in excellent reviews [88–91]. Curcumin, the major constituent in the rhizome of Curcuma longa has been shown to display potent schistosomicidal activities in vivo and in vitro against adult S. mansoni worms [92–96]. The most successful product was myrrh, an oleo-gum resin extracted from the stem of Commiphora molmol [97], believed to affect schistosome musculature, leading to uncoupling of male and female couples and their extravasation to the liver tissue [98]. The product has been licensed for human use by the Egyptian Ministry of Health, and introduced in the Egyptian market in the form of gelatinous capsules by the pharmaceutical company, Pharco (Alexandria, Egypt) under the name of Mirazid. However, conflicting reports on its efficacy shed doubts upon the usefulness of its use as a novel therapy for schistosomiasis [98–103].

Arachidonic acid, a novel remedy for schistosomiasis

Mode of action

Our approach to the therapy of schistosomiasis is entirely novel and is herein clarified. Developing and adult schistosomes are covered by the tegument, a 2–4 μm thick syncytium. The innermost membrane of the tegument is a conventional membrane (the basal membrane), whereas the outer membrane on the syncytium is trilaminate in cercariae. By about 3 h after penetration, the trilaminate outer membrane of the cercariae is gradually replaced by a unique heptalaminate membrane, widely believed to cause protection against elements of the host immune system. Notably, the surface membrane at the parasite/host interface consists of two tightly apposed bilayers, the inner and outer bilayers, each of which is composed of inner and outer leaflets [104]. As for conventional plasma membranes, proteins are embedded in schistosome outer and inner lipid bilayers among phosphoglycerides, cholesterol and sphingomyelin molecules [105]. Conversely from conventional plasma membranes, proteins in the schistosome outer lipid bilayer are concealed, hidden, and totally inaccessible to host antibodies. We have recently shown that this major immune evasion phenomenon is due to the sphingomyelin of the outer lipid bilayer, likely via concealment of surface membrane proteins behind a tight barrier of hydrogen bonds sphingomyelin readily forms with water molecules [106–110]. Sphingomyelin hydrolysis is catalyzed by a group of enzymes called sphingomyelinases, yielding ceramide and phosphorylcholine. Many sphingomyelinase activities have been identified and may be classified into two main groups. The acid forms function at an optimal pH of 4.5, and are found in the cell acidic compartments. The neutral forms function at a neutral pH and are found in different locations within the cell, especially the outer membrane [111]. Tegument-bound neutral sphingomyelinase (nSMase) activity is optimal at pH > 7.4, exhibits an absolute dependence on magnesium or manganese (2 and 10 mM for Mg2+ and up to 2.5 mM for Mn2+), and is readily inhibited by the compound GW4869 [112]. Like mammalian nSMase [111–113], S. mansoni tegument-associated nSMase activity is increased several folds, in vitro and in vivo, by polyunsaturated fatty acids, especially arachidonic acid (ARA) [114–116]. We have documented that in vitro treatment of lung-stage schistosomula and adult worms with unsaturated fatty acids, especially ARA, leads to exposure of otherwise hidden surface membrane antigens to specific antibody binding [106,109,110,117]. More importantly, feeding S. mansoni or S. haematobium-infected mice with unsaturated fatty acids-enriched food led to significant (P < 0.02) decrease in worm burden [109]. Accordingly, we proposed that ARA may represent a novel remedy for schistosomiasis.

Arachidonic acid properties

Arachidonic acid (ARA) is an omega-6 fatty acid: 20:4(ω-6), with a 20-carbon chain and four cis double bonds; the first double bond located at the sixth carbon from the omega end (Fig. 1). It is present in the phospholipids of membranes of the body’s cells, and is abundant in the brain. The ARA four cis double bonds (Fig. 1) are the source of its flexibility, keeping the pure fatty acid liquid, even at subzero temperatures, and helping to give mammalian cell membranes their correct fluidity at physiological temperatures. The double bonds are also the key to the propensity of ARA to react with molecular oxygen. This can happen nonenzymatically, contributing to oxidative stress, or through the actions of three types of oxygenase: cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P450 [118,119].

Proposing intake of exogenous ARA could be met with awe, as ARA may be metabolized to end products that produce pain and inflammation, namely the prostaglandins (COX pathway), which are mediators of the vascular phases of inflammation, are potent vasodilators, and increase vascular permeability; prostacycline (vasodilator and reduces platelet aggregation); thromboxane (increases vasoconstriction and platelet aggregation); and leukotrienes (LOX pathway) that are important mediators of inflammation. Of great concern too, is the fact that exogenous ARA is acted upon by COX and LOX enzymes, despite that many of which are located on the endoplasmic reticulum or nuclear membrane [118,119].

We have embarked on use of ARA for schistosomiasis therapy sure of the fact that ARA is an essential constituent of membrane lipids, and is the base material used by the body to synthesize a key series of hormones referred to collectively as dienolic prostaglandins (PG) that include the prostaglandins PGE2 and PGF2a. Proper development of the brain, retina and other body tissues depends upon provision of ARA either

Fig. 1 Arachidonic acid structure.
directly in the diet or through synthesis from linoleic acid (LA). Additionally, ARA is an essential fatty acid, which is consumed in our regular diets. It is found mainly in lean meat, egg yolks and some fish oils. Tissue ARA pools originate from the diet, and from hepatic and extrhepatic desaturation–elongation of dietary LA; in humans who ingest 0.2–0.3 g of ARA and 10–20 g of LA per day on a Western diet the formation of ARA from LA exceeds the dietary supply of ARA [120]. Indeed, most evidence supports that ingestion of moderate amounts of ARA is not disadvantageous. In a series of studies, humans ingested a diet containing 1.7 g of ARA per day for 50 days, and were then extensively studied. Dietary ARA at these levels nearly doubled ARA levels in the plasma phospholipids and cholesteryl ester, whereby ARA mainly replaced LA, which was reduced by 20%. Some increases in platelets, red blood cells, and tissue lipids were also found, but no significant increase in ARA was seen in adipose tissue triglycerides and phospholipids. The plasma free fatty acids showed a small but statistically significant rise in the ARA level. No harmful effects could be proven during the studies, although an increased production of eicosanoids was observed [121].

It is of note that ingestion of ω-3 essential fatty acids, namely EPA (eicosapentaenoic acid) entirely protects from any inflammatory effect ARA might elicit, by displacement, competitive inhibition, and direct counteraction. Docosahexaenoic acid (DHA) was reported to have an effect similar to EPA [122,123]. DHA is an omega-3 essential fatty acid, 22:6(ω-3), with a 22-carbon chain and six cis double bonds; the first double bond located at the third carbon from the omega end. Fortunately, Martek Biosciences Corporation recently produced infant formulas and capsules containing ARA (ARASCO®) and DHA. Using controlled fermentation conditions, Martek Biosciences obtains ARA from the soil fungus Mortierella alpina, and DHA from the non-photosynthetic marine micro-algae Crypthecodinium cohnii, products of proven entire safety [124]. Molecular Nutrition Company developed X-Factor, Arachidonic Acid as a food supplement during exercise. X Factor™ Arachidonic Acid is provided in the form of Softgels containing each 250 mg ARA, whereby 1 to 3 Softgels are recommended per day. In addition, ARA (ARASCO®, Martek Biosciences Corporation) was recently allowed to be added to infant formulas.

Schistosomicidal effects in vitro and in vivo

In our studies, pure ARA from Sigma was used for in vitro and preliminary in vivo studies, while ARA from Martek was used for in vivo studies [125,126]. We have demonstrated that 5 mM pure ARA (Sigma) leads to irreversible killing of ex vivo 1, 3, 4, 5, and 6 week-old S. mansoni and 9, 10 and 12 week-old S. haematobium worms, within 3–4 h, depending on the parasite age, even when worms were maintained in up to 50% fetal calf serum. ARA-mediated worm attrition was prevented by nSMase inhibitors such as CaCl₂ and GW4869. Scanning and transmission electron microscopy revealed that ARA-mediated worm killing was associated with spine destruction, membrane blebbing, and disorganization of the apical membrane structure [125]. ARA-mediated S. mansoni and S. haematobium worm attrition was reproduced in vivo whereby a series of 20 independent experiments using BALB/c or C57BL/6 mice, or hamsters indicated that ARA in a pure form (Sigma), included in infant formula (Nestle), or capsules (X Factor, Molecular Nutrition) consistently led to between 50% and 80% decrease in S. mansoni or S. haematobium worm burden [125,126]. ARA-mediated attrition in vivo appeared to be associated with high titers of serum antibodies to tegumental antigens. In support, serum antibodies from patenty-infected and ARA-administered hamsters readily bound to the surface membrane of ARA-treated, but not untreated, adult worms, as judged by indirect membrane immunofluorescence. More importantly, addition of serum antibodies and peripheral blood mononuclear cells significantly enhanced ARA-mediated adult worm attrition in vitro [126]. Immune responses to adult worm tegumental antigens are certainly more powerful in adults and children with patent infection than in hamsters, and ARA is already marketed for human use in USA and Canada for proper development of newborns, and muscle growth of athletes. Accordingly, it is recommended to start pre-clinical and clinical studies in human volunteers for development of ARA as a safe and cost-effective remedy to schistosomiasis, especially that no ARA-related adverse effects were seen in any experiment in mice or hamsters. Indeed, no changes were observed between untreated and ARA-treated experimental hosts in serum levels of triglycerides or cholesterol, number of erythrocytes or platelets, thrombin or prothrombin values in accord with the numerous reports documenting the entire safety of ARA ingestion [125,126].

Vaccine candidates and trials

The possibility of developing an effective vaccine for schistosomiasis stemmed from the highly significant protection obtained in experimental hosts using irradiated cercariae [reviewed in 127] and from the identification of humans resistant to schistosomiasis. Individuals classified as “endemic normals” are repeatedly exposed to infective cercariae and yet have no record of previous or current infection, and appear uninfected as judged by repeated stool examination. “Resistant” subjects are those whose stool and urine samples remain negative for eggs or show very low levels of reinfection following drug treatment of previous S. mansoni or S. haematobium infection despite unequivocal evidence of continued and high contact with schistosome-contaminated watersources [128–135]. The first subunit vaccine candidate antigens discovery was based on these models, whereby antibodies from irradiated cercariae (RA) vaccine-immunized mice and resistant individuals were used to screen schistosome cDNA libraries. These studies led to identification of S. mansoni irradiation associated vaccine antigen, IrV 5 [136,137], glutathione-S-transferase, GST [138,139], triosephosphate isomerase, TPI [140–142], paramyxosin [131,143,144], fatty acid binding protein, Sm 14, [145], the surface membrane antigen Sm23 [146–148], the calcium-dependent cysteine protease, calpain [4,149], and glyceraldehyde 3-phosphate dehydrogenase [130,150,151]. We have challenged the unique use of serum antibodies for selection of schistosome candidate vaccine antigens, because of the extensive cross-reactivity of B cell epitopes and the need to ascertain that the selected antigen is able to induce T cell help. Accordingly, we have used the T cell western technique to examine the proliferative and cytokine production activity of mouse spleen cells (SC) and human peripheral blood mononuclear cells (PBMC) in response to electroseparated and electrobotted soluble adult worm antigens (SAWA). Extensive analyses of the T and B cell reactivity of gamma or ultraviolet-irradiated cercariae-immunized inbred and outbred mice
to separated SAWA antigens [152–154] led to identification of 
* S. mansoni* enolase [152,155] and calreticulin [156] as the anti-
gens preferentially recognized by RA vaccinated mice. Studies 
using PBMC and sera obtained from endemic resistant humans 
or individuals resistant to reinfection after PZQ treatment 
ended into rediscovery of glyceraldehyde 3-phosphate dehydro-
genase (SG3PDH) as potential candidate vaccine antigen 
[134,135]. The cDNA encoding the full length molecule was 
cloned and expressed by Charles Shoemaker, and SG3PDH 
joined the group of candidate vaccine antigens, IrV5, paramy-
osin, GST, TPI, Sm14, Sm23, and calpain selected by the World 
Health Organization (WHO) for *in vitro* and *in vivo* trials. The 
*in vitro* studies using PBMC and sera of Egyptian [157] and Bra-
zilian [158] donors led to inconclusive answers, while the *in vivo* 
trials in inbred mice indicated that none of the vaccine candidate 
antigens induced higher than 40% reduction in challenge worm 
burden, the benchmark set by the WHO for progression of 
challenges vaccine antigens into clinical trials [159].

The *S. mansoni* fatty acid-binding protein, Sm14 antigen 
stands out, due to its steady progress towards field trials. Work 
has now progressed to the scale-up level and an industrial pro-
duction process has successfully been put in place [160]. *S. mansoni* calpain in recombinant DNA constructs appeared 
as successful, inducing protection levels higher than 50% in 
C57BL/6 mice and baboons vaccinated with the immunogen 
emulsified in complete Freund’s adjuvant, alum, or CpG 
[4,161,162]. Numerous protection trials were subsequently performed 
in outbred and inbred mice using SG3PDH, in a 
recombinant or peptidic form. Peptides with lowest homology 
to the human counterpart synthesized as linear, monopeptidic 
or dipeptidic multiple antigen peptide (MAP) constructs, or 
full length recombinant SG3PDH were used in conjunction 
with complete (CFA) or incomplete (IFA) Freund’s adjuvant, 
alum, or TiterMax adjuvant, leading to protection levels 
between 10 and 35% [163–166 and references therein].

The failure with SG3PDH was ascribed to the fact that 
the potential candidate vaccine antigens must be located at 
the host-parasite interface to be accessible to antibody-depend-
ent cell-mediated cytotoxicity (ADCC) the once thought 
thought plausible mechanism of schistosome elimination. We have 
used as immunogen the *S. mansoni* glucose transporter, 
SGTP4, cloned and sequenced by Patrick Skelly and Charles 
Shoemaker [167]. We have circumvented the poor immunog-
enicity and strong hydrophobicity of the molecule that pos-
sesses 12 transmembrane domains, by using the large 
extracellular loop in a recombinant form, and the other extra-
cellular stretches as synthetic linear peptides. Extensive stud-
ies in C57BL/6, BALB/c, and outbred CD1 mice immunized 
with SGTP4 in a recombinant or peptidic form in conjunc-
tion with CFA and IFA resulted in lack of protection 
against challenge *S. mansoni* infection, despite considerable 
specific humoral and cellular immune responses [168]. More 
recently, the *S. mansoni* integral surface membrane proteins 
tetraspanins (TSP-1) and TSP-2 encoding cDNA were cloned, 
sequenced, and expressed and showed to elicit protection levels 
of 57% and 64% (TSP-2) and 34% and 52% (TSP-1) for 
mean adult worm burdens and liver egg burdens, respectively, 
to over two independent trials in CBA/CaH mice [169]. The pro-
tection levels were not reproduced using *S. japonicum* coun-
terpart, whereby mice immunized with the recombinant 
protein of a single TSP-2 subclass showed no protection, 
while immunization with a mixture of seven recombinant 
TSP-2 subclasses provided a moderate protection [170]. The 
failure in inducing consistent protection was ascribed to polym-
orphism in the extracellular site used for vaccination [170–
172]. A recent study used *S. mansoni* TSP-2 extracellular loop 
2 region in conjunction with alum and CpG as adjuvants and 
reported extremely variable protection levels against chal-
lenge infection within cohorts of highly inbred C57BL/6 mice 
[173].

**Novel prevention approaches**

Up to today, there is no available vaccine for schistosomiasis. 
One major reason for this failure resides in selecting unsuitable 
vaccine candidates. Thus, it is not clear how the host immune 
effector elements would eliminate parasites via interacting with 
internal and cytosolic proteins such as paramyosin, fatty acid 
binding protein, GST, TPI, or SG3PDH [164,174]. Addition-
ally, surface membrane antigens are hidden in the developing 
larvae and adult worms and, hence, are entirely inaccessible 
to the host immune system unless the parasite is suffering 
additional loss of tegument integrity and poised to die [106–
110,175–177]. Conversely, viable lung schistosomula excre-
tory–secretory products (ESP) are ideal potential vaccines. 
ESP can readily play a central role in induction of local pri-
mary and memory immune responses, and are available targets 
to the effector immune elements, mediating generation of imm-
une effectors, toxic radicals, and inflammatory cytokines 
and cells that would directly target, surround, and pursue 
the larvae while painstakingly negotiating the tight lung capil-
laries [178].

Accordingly, schistosomula were separated from BALB/c 
lung 6 days after infection with cercariae of *S. mansoni*, iso-
lated free of host erythrocytes and lung cells, and cultured 
for 48 h in protein-free medium under conditions that entirely 
preserved the viability of larvae and any remaining cells. The 
released ESP proteins were minute in quantity, corroborating 
the results obtained with *in vitro*-grown lung larvae [179,180], 
yet were highly immunogenic in BALB/c mice, inducing pro-
duction of specific antibodies, and expression of mRNA for interleukin (IL)-12p40, interleu- 
feron-gamma (IFN-γ) and tumor 

carcinoma–factor-alpha (TNF-α) [178]. Proteinomic analysis of the 
ESP molecules of 25, 28 and 40 kDa revealed sequences 
belonging to innumerable rodent host-derived and a few 
*S. mansoni*-specific proteins. *S. mansoni* fructose 1,6 biphosphate aldolase (aldolase) and calpain were previously identified 
in products released from *in vitro*-cultured *S. mansoni* lung schis-\n
tosomula [179]. Additionally, *ex vivo* lung stage schistosomula 
were found to release TPI, GST, SG3PDH, and 2-cys-perox-
yreoxidin (thioredoxin peroxidase, TPX) together with cyto-
solic molecules such as 14-3-3 protein homologue 1, actin 
and histone. It is of note that calpain, aldolase, TPI, GST, 
SG3PDH, TPX, and 14-3-3 protein homolog1 were detected 
among soluble proteins of *in vitro*-grown day 8 *S. mansoni* 
chitosomula [181], and secretions of *S. mansoni* cercariae 
[182,183]. The status of many of these molecules as vaccine 
candidates was made understood, as they are readily excreted-secreted by intact larvae and are, hence, entirely access-
sible to the host immune system effector elements [178].

In the vasculature, larval ESP and endothelial cells-
associated co-stimulatory molecules [184] induce T helper
(Th) lymphocytes to release cytokines, which activate monocytes, basophils, eosinophils, and neutrophils to target and eliminate the migrating larvae. ESP interaction with specific antibodies may also trigger myeloid cells towards participating in the killing of migrating larvae. It is documented that larval antigens induce Th1 immune responses [180,185,186]. Additionally, MAP construct containing S. mansoni TPI-derived T- and B-cell epitopes was able to trigger naïve donor immune responses towards a type-1 cytokine profile, consisting mainly of IFN-γ [187]. We have repeatedly observed that 14-3-3-like antigen and TPX stimulate strong IFN-γ and interleukin (IL)-17-driven responses in SC obtained from naïve mice and mice 7 days after S. mansoni infection, while rSG3PDH and TPX-derived peptide induced slightly lower levels of these cytokines and a small amount of IL-4 [188].

Th1 inflammatory cytokines such as IFN-γ and TNF-α trigger monocytes and endothelial cells to release the potentially larvadicidal superoxide anions and oxygen and nitrogen radicals, and the pro-inflammatory cytokines, IL-1, IL-6, and IL-23 [189,190]. Monocytes activation generates high levels of hydrogen peroxide and nitric oxide, which might be lethal to many parasites [191,192], but may induce others to tighten their protective outer double lipid membrane, via inactivation of tegument-associated neutral sphingomyelinase [110]. Additionally, activated neutrophils recruited to the site by ESP-induced IL-17 [188,193] can release a range of toxic species and web-like structures termed neutrophil extracellular traps that entrap the larvae within the vasculature [189,190,194]. Eosinophils and basophils, activated via binding ESP-antibody complexes or type 2 cytokines, may release larvacidal molecules and pro-inflammatory mediators in the vicinity of the migrating larvae, and produce factors that alter the blood capillary permeability via disrupting endothelial integrity [194]. Larval ESP, however, are known to induce Th1 and Th17 cytokine-driven responses, thus hindering the recruitment, and activation of eosinophils and basophils.

To engage eosinophils and basophils in the hunt of migrating larvae, outbred, akin to humans, mice were immunized with 10 μg recombinant SG3PDH and 15 μg TPX-derived peptide in conjugation with 10 μg of the cysteine protease papain, or 200 ng of the type 2 cytokines, thymic stromal lymphopoietin, IL-25, or IL-33 as adjuvant [195–200]. Two weeks later, untreated, adjuvant controls, and immunized mice were challenged with 100 or 125 cercariae. Results of 8 separate experiments indicated that these formulations elicited IgM, IgG1, and IgA specific antibodies, and increase in ex vivo SC release of IL-4 and IL-5, correlated with highly significant (up to P < 0.0001) reduction of 62–78% in challenge worm burden [200].

Improvement of ESP selection, singly or in a combination, and immunization regimen, namely ESP and type-2 cytokine dose and injection site and schedule, will likely lead to a sterilizing schistosomiasis vaccine in a foreseeable future.

Acknowledgments

Experiments related to novel approaches to therapy and vaccinations were supported, in part, by the Science and Technology Development Fund, Egypt, Grants No. 144 and 2073 to R. El Ridi.

References

[1] Steinmann P, Keiser J, Bos R, Tanner M, Uitzinger J. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis 2006;6:411–25.
[2] King CH. Parasites and poverty: the case of schistosomiasis. Acta Trop 2010;113:95–104.
[3] Gray DJ, McManus DP, Li Y, Williams GM, Bergquist R, Ross AG. Schistosomiasis elimination: lessons from the past, guide the future. Lancet Infect Dis 2010;10:733–6.
[4] Siddiqui AA, Siddiqui BA, Ganley-Leal L. Schistosomiasis vaccines. Hum Vaccin 2011;7:1192–7.
[5] Uitzinger J, Raso G, Brooker S, De Savigny D, Tanner M, Ornberg N, et al. Schistosomiasis and neglected tropical diseases: towards integrated and sustainable control and a word of caution. Parasitology 2009;136:1859–74.
[6] Hotez PJ. The neglected tropical diseases and their devastating health and economic impact on the member nations of the organisation of the Islamic conference. PLoS Negl Trop Dis 2009;3:e539.
[7] Hotez PJ, Savioli L, Fenwick A. Neglected tropical diseases of the middle east and north Africa: review of their prevalence, distribution, and opportunities for control. PLoS Negl Trop Dis 2011;5:e1475.
[8] Curwen RS, Wilson RA. Invasion of skin by schistosome cercariae: some neglected facts. Trends Parasitol 2003;19:63–6.
[9] He YX, Salafsky B, Ramaswamy K. Comparison of skin invasion among three major species of Schistosoma. Trends Parasitol 2005;21:201–3.
[10] Rheinberg CE, Moné H, Caffrey CR, Imbert-Establet D, Jourdane J, Ruppel A. Schistosoma haematobium, S. intercalatum, S. japonicum, S. mansoni, S. rodhaini in mice: relationship between patterns of lung migration by schistosomula and perfusion recovery of adult worms. Parasitol Res 1998;84:338–42.
[11] Sturrock RF. The parasites and their life cycle. In: Jordan P, Webbe G, Sturrock RF, editors. Human schistosomiasis. Wallingford (UK): CAB International; 1993. p. 1–32.
[12] Farid Z. Schistosomes with terminal-spined eggs: pathological and clinical aspects. In: Jordan P, Webbe G, Sturrock RF, editors. Human schistosomiasis. Wallingford (UK): CAB International; 1993. p. 159–93.
[13] Andersson KL, Chung RT. Hepatic schistosomiasis. Curr Treat Options Gastroenterol 2007;10:504–12.
[14] Burke ML, Jones MK, Gobert GN, Li YS, Ellis MK, McManus DP. Immunopathogenesis of human schistosomiasis. Parasite Immunol 2009;3:163–76.
[15] Mbabazi PS, Andan O, Fitzgerald DW, Chitsulo L, Engels D, Downs JA. Examining the relationship between urogenital schistosomiasis and HIV infection. PLoS Negl Trop Dis 2011;5:e1396.
[16] Secor WE. The effects of schistosomiasis on HIV/AIDS infection, progression and transmission. Curr Opin HIV AIDS 2012;7:254–9.
[17] Strickland GT. Liver disease in Egypt: hepatitis C superseeded schistosomiasis as a result of iatrogenic and biological factors. Hepatology 2006;43:915–22.
[18] El-Zayadi AR, Hepatitis C. Comorbidities affecting the course and response to therapy. World J Gastroenterol 2009;15:4993–9.
[19] Abruzzi A, Fried B. Coinfection of Schistosoma (Trematoda) with bacteria, protozoa and helminths. Adv Parasitol 2011;77:1–85.
[20] Baeing E, Fisher J. Factors affecting the inhibition of phosphofructokinase activity of Schistosoma mansoni by...
trivalent organic antimonials. Biochem Pharmacol 1966;11:1197–211.
[21] Denham DA, Holdsworth RJ. The effect of metrifonate in vitro on Schistosoma haematobium and Schistosoma mansoni adults. Trans Roy Soc Trop Med Hyg 1971;65:969.
[22] Holmstedt B, Nordgren I, Sandoz M, Sundwall A. Metrifonate. Summary of toxicological and pharmacological information available. Arch Toxicol 1978;41:3–29.
[23] Forsyth DM. Treatment of urinary schistosomiasis: practice and theory. Lancet 1965;2:354–8.
[24] Bergquist R. Strategies for control of infection and disease: current practice and future potential. In: Mahmood AAF, editor. Schistosomiasis. London: Imperial College Press; 2001. p. 413–67.
[25] Foster R, Cheetham BL. Studies with the schistosomicide oxamnique (UK-4271). I. Activity in primates. Trans Roy Soc Trop Med Hyg 1973;67:685–93.
[26] Foster R. A review of clinical experience with oxamnique. Trans Roy Soc Trop Med Hyg 1987;81:55–9.
[27] Pica-Mattoccia L, Cioli D. Studies on the mode of action of oxamnique and related schistosomicidal drugs. Am J Trop Med Hyg 1985;34:112–8.
[28] Cioli D, Pica-Mattoccia L, Archer S. Antischistosomal drugs: past, present … and future? Pharmoc Ther 1995;68:35–85.
[29] Davis A. Antischistosomal drugs and clinical practice. In: Jordan P, Webbe G, Starrook RF, editors. Human schistosomiasis. Wallingford: CAB International; 1993. p. 367–404.
[30] Kumar V, Gryseels B. Use of praziquantel against schistosomiasis: a review of current status. Int J Antimicrob Agents 1994;4:313–20.
[31] Xiao SH, Catto BA, Webster LT. Effects of praziquantel on different developmental stages of oxamnique and related schistosomical drugs. Trans R Soc Trop Med Hyg 1985;39:241–6.
[32] Mehlhorn H, Becker B, Andrews P, Thomas H, Frenkel JK. In vivo and in vitro experiments on the effects of praziquantel on Schistosoma mansoni. A light and electron microscopic study. Arzneim Forsch/Drug Res 1981;31:544–54.
[33] Andrews P. Praziquantel: mechanisms of anti-schistosomal activity. Pharmoc Ther 1985;29:129–56.
[34] Day TA, Bennett JL, Pax RA. Praziquantel: the enigmatic antiparasitic. Parasitol Today 1992;8:342–4.
[35] Kohn AB, Anderson PAV, Roberts-Misterly J, Greenberg RM. Schistosome calcium channel β subunits unusual modulatory effects and potential role in the action of the antischistosomal drug praziquantel. J Biol Chem 2001;276:36873–6.
[36] Greenberg RM. Ca2+ signalling, voltage-gated Ca2+ channels and praziquantel in flatworm neuromusculature. Parasitology 2005;131(Suppl):S97–S108.
[37] Jeziorski MC, Greenberg RM. Voltage-gated calcium channel subunits from platyhelminths: potential role in praziquantel action. Int J Parasitol 2006;36(36):625–32.
[38] Salvador-Recatalà V, Greenberg RM. Calcium channels of schistosomes: unresolved questions and unexpected answers. Wiley Interdiscip Rev Membr Transp Signal 2012;1:85–93.
[39] Doenhoff MJ, Cioli D, Utzinger J. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis 2008;21:659–77.
[40] Harder A, Goossens J, Andrews P. Influence of praziquantel and Ca2+ on the bilayer-isotropic-hexagonal transition of model membranes. Mol Biochem Parasitol 1988;29:55–60.
[41] Schepers H, Lussier R, Goormaghtigh E, Duguenoy JM, Ruysschaert JM. Mode of insertion of praziquantel and derivatives into lipid membranes. Biochem Pharmacol 1987;37:1615–23.
[42] Lima SF, Vieira LQ, Harder A, Kusel JR. Altered behaviour of carbohydrate-bound molecules and lipids in areas of the tegument of adult Schistosoma mansoni worms damaged by praziquantel. Parasitology 1994;100:469–77.
[43] Fenwick A, Savioli L, Engels D, Bergequist NR, Todd MH. Drugs for the control of parasitic diseases: current status and development in schistosomiasis. Trends Parasitol 2003;19:509–15.
[44] Doenhoff MJ, Hagan P, Cioli D, Southgate V, Pica-Mattoccia L, Botros S, et al. Praziquantel: its use in control of schistosomiasis in sub-Saharan Africa and current research needs. Parasitology 2009;136:1825–35.
[45] Stothard JR, Sousa-Figueiredo JC, Betsom M, Green KH, Seto EY, Garba A, et al. Closing the praziquantel treatment gap: new steps in epidemiological monitoring and control of schistosomiasis in African infants and preschool-aged children. Parasitology 2011;138:593–606.
[46] Oshish A, AlKohlani A, Hamed A, Kamel N, AlSoofi A, Farouk H, et al. Towards nationwide control of schistosomiasis in Yemen: a pilot project to expand treatment to the whole community. Trans Roy Soc Trop Med Hyg 2011;105:617–27.
[47] Leslie J, Garba A, Oliva EB, Barkire A, Tinni AA, Djibio A, et al. Schistosomiasis and soil-transmitted helminth control in Niger: effect of school based community distributed mass drug administration. PLoS Negl Trop Dis 2011;5:e1326.
[48] Gryseels B, Mbaye A, De Vlas SJ, Stelma FF, Guisse F, Van Lieshout L, et al. Are poor responses to praziquantel for the treatment of Schistosoma mansoni infections in Senegal due to resistance? An overview of the evidence. Trop Med Int Health 2001;6:864–73.
[49] Raso G, N’Goran EK, Totty A, Luginbuhl A, Adjoua CA, Tian-Bi NT, et al. Efficacy and side effects of praziquantel against Schistosoma mansoni in a community of western Cote d’Ivoire. Trans Roy Soc Trop Med Hyg 2004;98:18–27.
[50] Barakat R, El Morshedy H. Efficacy of two praziquantel treatments among primary school children in an area of high Schistosoma mansoni endemicity, Nile Delta, Egypt. Parasitology 2011;138:440–6.
[51] Fallon PG, Tao LF, Ismail MM, Bennett JL. Schistosome resistance to praziquantel: fact or artifact? Parasitol Today 1996;12:316–20.
[52] Bennett JL, Day T, Feng-Tao L, Ismail M, Farghaly A. The development of resistance to anthelmintics: a perspective with an emphasis on the antischistosomal drug praziquantel. Exp Parasitol 1997;87:260–7.
[53] Kusel J, Hagan P, Praziquantel – its use, cost and possible development of resistance. Parasitol Today 1999;15:352–4.
[54] Ismail M, Botros S, Metwally A, Williams S, Farghally A, Tao LF, et al. Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers. Am J Trop Med Hyg 1999;60:932–5.
[55] Sabra AN, Botros SS. Response of Schistosoma mansoni isolates having different drug sensitivity to praziquantel over several life cycle passages with and without therapeutic pressure. J Parasitol 2008;94:537–41.
[56] Linder E, Thors C. Schistosoma mansoni: praziquantel-induced tegumental lesion exposes actin of surface spines and allows binding of actin depolymerizing factor, gelsolin. Parasitology 1992;105:71–9.
[57] Tallima H, El Ridi R. Praziquantel binds Schistosoma mansoni adult worm actin. Int J Antimicrob Agents 2007;29:570–5.
[58] Tallima H, El Ridi R. Re: is actin the praziquantel receptor? Int J Antimicrob Agents 2007;29:566–7.
[59] Pica-Mattoccia L, Velle C, Basso A, Troiani AR, Vigorosi F, Liberti P, et al. Cytochalan D abolishes the schistosomicidal activity of praziquantel. Exp Parasitol 2007;115:344–51.
[60] Gnanasekar M, Salunke AM, Mallia AK, He YX, Kalyanasundaram R. Praziquantel affects the regulatory
myosin light chain of *Schistosoma mansoni*. Antimicrob Agents Chemother 2009;53:1054–60.

[61] Richard-Lenoble D, Chandenier J, Duong TH. Antiparasitic treatments in pregnant women and in children in 2003. Med Trop (Mars) 2003;63:491–7.

[62] Liu H, William S, Herdtweck E, Botros S, Dömling A. MCR synthesis of praziquantel derivatives. Chem Biol Drug Des 2012;79:470–7.

[63] Menezes CM, Rivera G, Alves MA, Do Amaral DN, Thibaut JP, Noël F, et al. Synthesis, biological evaluation and structure-activity relationship of clonazepam, meclonazepam and 1,4-benzodiazepine compounds with schistosomicidal activity. Chem Biol Drug Des 2012;79:943–9.

[64] N’Goran EK, Utzinger J, Gnaka HN, Yapi A, N’Guessan NA, Kigbafori SD, et al. Randomized, double-blind, placebo-controlled trial of oral artemether for the prevention of patent *Schistosoma haematobium* infections. Am J Trop Med Hyg 2003;68:24–32.

[65] Utzinger J, Chollet J, You J, Mei J, Tanner M, Xiao S. Effect of combined treatment with praziquantel and artemether on *Schistosoma japonicum* and *Schistosoma mansoni* in experimentally infected animals. Acta Trop 2001;80:9–18.

[66] Utzinger J, Keiser J, Singh BH. Combination chemotherapy of schistosomiasis in laboratory studies and clinical trials. Antimicrob Agents Chemother 2003;47:1487–95.

[67] Mahmoud MR, Botros SS. Artemether as adjuvant therapy to praziquantel in murine Egyptian *Schistosoma mansoni*. J Parasitol 2005;91:175–8.

[68] Botros SS, Hammam O, Mahmoud M, Bergquist R. Praziquantel efficacy in mice infected with PQZ non-susceptible *S. mansoni* isolate treated with artemether: parasitological, biochemical and immunohistochemical assessment. APMS 2010;118:692–702.

[69] El-Lakkany NM, Hammam OA, El-Maadawy WH, Badawy AA, Ain-Shoka AA, Ebeid FA. Anti-inflammatory/anti-fibrotic effects of the hepatoprotective silymarin and the schistosomicide praziquantel against *Schistosoma mansoni*-induced liver fibrosis. Parasit Vectors 2012;5:9.

[70] Chen BL, Zhang GY, Wang SP, Li Q, Xu MH, Shen YM, et al. The combined treatment of praziquantel with osteopontin immunoneutralization reduces liver damage in *Schistosoma japonicum*-infected mice. Parasitology 2012;139:522–9.

[71] Xiao S, Tanner M, N’Goran EK, Utzinger J, Chollet J, Bergquist R, et al. Recent investigations of artemether, a novel agent for the prevention of schistosomiasis japonica, *S. mansoni* and *haematobium*. Acta Trop 2002;82:175–81.

[72] Xiao SH, Catto BA. *In vitro* and *in vivo* studies of the effect of artemether on *Schistosoma mansoni*. Antimicrob Agents Chemother 1989;33:1557–62.

[73] Xiao S, Utzinger J, Chollet J, Endriss Y, N’Goran EK, Tanner M. Effect of artemether against *Schistosoma haematobium* in experimentally infected hamsters. Int J Parasitol 2000;30:1001–6.

[74] Utzinger J, Xiao SH, Tanner M, Keiser J. Artemisinins for schistosomicides and vaccines. *Current topics in tropical medicine*. InTech Open; 2012. p. 27–70. <http://www.intechopen.com/books/schistosomiasis/the-use-of-brazilian-medicinal-plants-to-combat-schistosoma-mansoni>

[75] De Moraes J. Antischistosomal natural compounds: present challenges for new drug screens. In: Rodriguez-Moraes A, editor. Current topics in tropical medicine. InTech Open; 2012. p. 323–57. <http://www.intechopen.com/books/schistosomiasis/the-use-of-brazilian-medicinal-plants-to-combat-schistosoma-mansoni>

[76] El-Ansary AK, Ahmed SA, Aly SA. Antischistosomal and liver protective effects of Curcuma longa extract in *Schistosoma mansoni* infected mice. Indian J Exp Biol 2007;45:791–801.
[132] Hagan P, Blumenthal UJ, Dunn D, Simpson AJG, Wilkins HA. Human IgE, IgG4 and resistance to reinfection with *Schistosoma haematobium*. Nature 1991;349:243–5.

[133] Viana IR, Sher A, Carvalho OS, Massara CL, Eloi-Santos SM, Pearce EI, et al. Interferon-gamma production by peripheral blood mononuclear cells from residents of an area endemic for *Schistosoma mansoni*. Trans Roy Soc Trop Med Hyg 1994;88:466–70.

[134] El Ridi R, Farouk F, Sherif M, Ali-Sherbiny M, Osman A, El Gengehi N, et al. T and B cell reactivity to a 42-kDa protein is associated with human resistance to both *Schistosomiasis mansoni* and haematobium. J Infect Dis 1998;177:1364–72.

[135] El Ridi R, Shoemaker CB, Farouk F, El Sherif NH, Afifi A. Human T- and B-cell responses to *Schistosoma mansoni* recombinant glyceraldehyde-3-phosphate dehydrogenase correlate with resistance to reinfection with *S. mansoni* or *Schistosoma haematobium* after chemotherapy. Infect Immun 2001;69:237–44.

[136] Soisson LM, Masterson CP, Tom TD, McNally MT, Lowell GH, Strand M. Induction of protective immunity in mice using a 62-kDa recombinant fragment of a *Schistosoma mansoni* surface antigen. J Immunol 1992;149:3612–20.

[137] Soisson LA, Reid GDF, Farah JO, Nyindo M, Strand M. Protective immunity in baboons vaccinated with a recombinant antigen or radiation-attenuated cercariae of *Schistosoma mansoni* is antibody-dependent. J Immunol 1993;151:4782–9.

[138] Balloul JM, Sondermeyer P, Dreyer D, Capron M, Grzych JM, Percie RD, et al. Molecular cloning of a protective antigen of schistosomes. Nature 1987;326:149–53.

[139] Boulanger D, Reid GD, Sturrock RF, Wolowczuk I, Balloul JM, Grezel D, et al. Immunization of mice and baboons with the recombinant Sm28GST affects both worm viability and fecundity after experimental infection with *Schistosoma mansoni*. Parasite Immunol 1991;13:473–90.

[140] Harn DA, Mitsuyama M, Huguenel ED, Oligino LD, Mitsuyama M, Gebremichael A, Richter D. A protective monoclonal antibody specifically recognizes and alters the catalytic activity of schistosome triose-phosphate isomerase. J Immunol 1992;148:562–7.

[141] Shoemaker C, Gross A, Gebremichael A, Harn D. CDNA cloning and functional expression of the *Schistosoma mansoni* triose-phosphate isomerase. J Immunol 1992;148:562–7.

[142] Harn DA, Wei G, Oligino LD, Mitsuyama M, Gebremichael A, Richter D. A protective monoclonal antibody specifically recognizes and alters the catalytic activity of schistosome triose-phosphate isomerase. Proc Natl Acad Sci USA 1992;89:1842–6.

[143] El Ridi R, Barbier D, lamitou J, Tallima H, Montash M, Veprek P, Velek J, Jezek J, El Ridi R. Immunogenicity and protective immunity of adult worm antigens recognized by T lymphocytes of outbred Swiss mice immunized with irradiated cercariae. Exp Parasitol 1993;76:265–77.

[144] Barakat R, El Morshedy H, Mudawi A, Al-Sherbiny M, Osman A, Barakat R, El Morshedy H, Mudawi A, Al-Sherbiny M, Osman A. T and B cell reactivity to a 42-kDa protein is associated with resistance to *Schistosomiasis mansoni*. Scand J Immunol 2001;54:477–85.

[145] Karcz SR, Podesta RB, Siddiqui AA, Dekaban GA, Strejan GH, Clarke MW. Molecular cloning and sequence analysis of a calcium-activated neutral protease (calpain) from *Schistosoma mansoni*. Mol Biochem Parasitol 1991;49:333–6.

[146] Goudot-Crozel V, Caillol D, Djabali M, Dessein AJ. The major parasite surface antigen associated with human resistance to schistosomiasis is a 37-kD glyceraldehyde-3-phosphate dehydrogenase. J Exp Med 1989;170:2065–80.

[147] Charrier-Ferrara S, Caillol D, Goudot-Crozel V. Complete sequence of the *Schistosoma mansoni* glyceraldehyde-3-phosphate dehydrogenase gene encoding a major surface antigen. Mol Biochem Parasitol 1992;56:339–43.

[148] El Ridi R, Abdel Tawab N, Guirguis N. *Schistosoma mansoni*: identification and protective immunity of adult worm antigens recognized by T lymphocytes of outbred Swiss mice immunized with irradiated cercariae. Exp Parasitol 1993;76:265–77.

[149] Oman A, El Ridi R, Guirguis N, Dean DA. Identification of *Schistosoma mansoni* antigens recognized by T cells of C57BL/6 mice immunized with gamma-irradiated cercariae. J Parasitol 1994;80:421–31.

[150] Oman A, El Ridi R, Guirguis N, Dean DA. Identification of *Schistosoma mansoni* antigens recognized by spleen cells of C57BL/6 mice immunized with ultraviolet-irradiated cercariae. Int J Parasitol 1994;24:943–50.

[151] Abdel Tawab N. Identification and molecular characterization of protective antigens against murine *Schistosomiasis mansoni*. Ph.D thesis. Faculty of Science, Cairo University; 1994. p. 280.

[152] El Gengehi N, El Ridi R, Tawab NA, El Denehawy M, Mangold BL. *A Schistosoma mansoni* 62-kDa band is identified as an irradiated vaccine T-cell antigen and characterized as cathepsin. J Parasitol 2000;86:993–1000.

[153] Al-Sherbiny M, Osman A, Barakat R, El Morsheyed H, Bergquist R, Olds R. In vitro cellular and humoral responses to *Schistosoma mansoni* vaccine candidate antigens. Acta Trop 2003;88:117–30.

[154] Ribeiro de Jesus A, Araújo I, Bacellar O, Magalhães A, Pearce E, Harn D, et al. Human immune responses to *Schistosoma mansoni* vaccine candidate antigens. Infect Immun 2000;68:2797–803.

[155] Todd CW, Colley DG. Practical and ethical issues in the development of a vaccine against *Schistosomiasis mansoni*. Am J Trop Med Hyg 2002;66:348–58.

[156] Tendler M, Simpson AJ. The biotechnology-value chain: development of Sm14 as a schistosomiasis vaccine. Acta Trop 2008;108:263–6.

[157] Siddiqi AA, Ahmad G, Damian RT, Kennedy RC. Experimental vaccines in animal models for schistosomiasis. Parasitol Res 2008;102:825–33.

[158] Ahmad G, Zhang W, Torben W, Ahrorov A, Damian RT, Siddiqui AA, Ahmad G, Damian RT, Kennedy RC. Preclinical prophylactic efficacy testing of Sm-p80-based vaccine in a nonhuman primate model of *Schistosoma mansoni* infection and immunoglobulin G and E responses to Sm-p80 in human serum samples from an area where schistosomiasis is endemic. J Infect Dis 2011;204:1437–49.

[159] El Ridi R, Mahrous A, Afifi A, Montash M, Velev J, Jezek J. Human and murine humoral immune recognition of multiple peptides from *Schistosoma mansoni* glyceraldehyde-3-P dehydrogenase is associated with resistance to Schistosomiasis. Scand J Immunol 2001;54:477–85.

[160] Tallima H, Montash M, Yeprek P, Velev J, Jezek J, El Ridi R. Differences in immunogenicity and vaccine potential of peptides from *Schistosoma mansoni* glyceraldehyde-3-phosphate dehydrogenase. Vaccine 2003;21:3290–300.

[161] El Ridi R, Montash M, Tallima H. Immunogenicity and vaccine potential of dipeptidic multiple antigen peptides from *Schistosoma mansoni* glyceraldehyde-3-phosphate dehydrogenase. Scand J Immunol 2004;60:392–402.
Identification of novel proteases and immunomodulators in the secretions of schistosome cercariae that facilitate host entry. Mol Cell Proteomics 2006;5:835–44.

[184] Kroczeck RA, Mages HW, Hutloff A. Emerging paradigms of T-cell co-stimulation. Curr Opin Immunol 2004;16:321–7.

[185] Pearce EJ, Caspar P, Gryzch JM, Lewis FA, Sher A. Downregulation of Th1 cytokine production accompanies induction of Th2 responses by a parasitic helminth, Schistosoma mansoni. J Exp Med 1991;173:159–66.

[186] Coulson PS. The radiation-attenuated vaccine against schistosomes in animal models: paradigm for a human vaccine? Adv Parasitol 1997;39:271–336.

[187] Reis EA, Maaudi Carmo TA, Athanazio R, Reis MG, Harn Jr DA. Schistosoma mansoni triose phosphate isomerase peptide MAP4 is able to trigger naïve donor immune response towards a type-1 cytokine profile. Scand J Immunol 2008;68:169–76.

[188] El Ridi R, Tallima H, Mahana N, Dalton JP. Innate immunogenicity and in vitro protective potential of Schistosoma mansoni lung schistosomula excretory–secretory candidate vaccine antigens. Microbes Infect 2010;12:700–9.

[189] Dale DC, Boxer L, Liles WC. The phagocytes: neutrophils and monocytes. Blood 2008;112:335–45.

[190] Hickey M, Kubes P. Intravascular immunity: the host-pathogen encounter in blood vessels. Nat Rev Immunol 2009;9:364–75.

[191] Wynn TA, Oswald IP, Eltoum IA, Caspar P, Lowenstein CJ, Lewis FA, et al. Elevated expression of Th1 cytokines and nitric oxide synthase in the lungs of vaccinated mice after challenge infection with Schistosoma mansoni. J Immunol 1994;153:5200–9.

[192] Ahmed SF, Oswald IP, Caspar P, Hiensy S, Keefer L, Sher A, et al. Developmental differences determine larval susceptibility to nitric oxide-mediated killing in a murine model of vaccination against Schistosoma mansoni. Infect Immun 1997;65:219–26.

[193] Tallima H, Salah M, Guirguis FR, El Ridi R. Transforming growth factor-β and Th17 responses in innate resistance to murine Schistosomiasis mansoni. Cytokine 2009;48:239–45.

[194] Saadi S, Wrenshall LE, Platt JL. Regional manifestations and control of the immune system. FASEB J 2002;16:849–56.

[195] Humphreys NE, Xu D, Hepworth MR, Liew FY, Grenics RK, IL-33, a potent inducer of adaptive immunity to intestinal nematodes. J Immunol 2008;180:2443–9.

[196] Saenz SA, Taylor BC, Artis D. Welcome to the neighborhood: epithelial cell-derived cytokines license innate and adaptive immune responses at mucosal sites. Immuno Rev 2008;226:172–90.

[197] Tang H, Cao W, Kasturi SP, Ravindran R, Nakaya H, Kundu K, et al. The T helper type 2 response to cysteine proteases requires dendritic cell-basophil cooperation via ROS-mediated signaling. Nat Immunol 2010;11:608–17.

[198] Siracusa MC, Saenz SA, Hill DA, Kim BS, Headley MB, Doering TA, et al. TSLP promotes interleukin-3-independent basophil haematopoiesis and type 2 inflammation. Nature 2011;477:229–33.

[199] Neill DR, McKenzie AN. Nuocytes and beyond: new insights into helminth expulsion. Trends Parasitol 2011;27:214–21.

[200] El Ridi R, Tallima H. Vaccine-induced protection against murine Schistosoma mansoni with larval excretory–secretory antigens and papain or type-2 cytokines. J Parasitol 2013;99:194–202.